TRDA

Entrada Therapeutics Stock Analysis

AI Rating

Fair
  • Quality3/10
  • Growth↓ 0/10
  • Momentum↑ 7/10
Entrada Therapeutics sales and earnings growth
TRDA Growth
Low
  • Revenue Y/Y↓ -71.42%
  • EPS Y/Y↓ -252.69%
  • FCF Y/Y↓ -643.23%
Entrada Therapeutics gross and profit margin trends
TRDA Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -168.20%
  • ROIC↓ -25.40%
Entrada Therapeutics net debt vs free cash flow
TRDA Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Entrada Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗